Platelet serotonin level predicts survival in amyotrophic lateral sclerosis

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Dupuis, Luc ^a,b   Spreux Varoquaux, Odile ^c,d   Bensimon, Gilbert ^e,f,g   Jullien, Philippe ^d   Lacomblez, Lucette ^a,e,g   Salachas, François ^g   Bruneteau, Gaëlle ^g   Pradat, Pierre François ^g   Loeffler, Jean Philippe ^a,b   Meininger, Vincent ^e,g  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f CNRS   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; SEROTONIN;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; ABNORMAL LABORATORY RESULT; ADULT; AGE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BODY MASS; CELL LEVEL; CONTROLLED STUDY; COULOMETRY; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PREDICTION; PROGNOSIS; RISK ASSESSMENT; SEROTONIN BLOOD LEVEL; SURVIVAL TIME; THROMBOCYTE; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; METABOLISM; SURVIVAL;

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; HUMANS; HYDROXYINDOLEACETIC ACID; SEROTONIN; SURVIVAL ANALYSIS;

EID: 78149459499     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013346     Document Type: Article

References (40)

1. Ravits JM, La Spada AR (2009) ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73: 805-811.
2. Pradat PF, Bruneteau G, Gordon PH, Dupuis L, Bonnefont-Rousselot D, et al. (2009) Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. pp 1-6.
3. Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, et al. (2001) Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 74: 328-334.
4. Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, et al. (1999) Nutritional status is a prognostic factor for survival in ALS patients. Neurology 53: 1059-1063.
5. Funalot B, Desport JC, Sturtz F, Camu W, Couratier P (2008) High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. pp 1-5.
6. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, et al. (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70: 1004-1009.
7. Heckman CJ, Mottram C, Quinlan K, Theiss R, Schuster J (2009) Motoneuron excitability: The importance of neuromodulatory inputs. Clin Neurophysiol.
8. Rekling JC, Funk GD, Bayliss DA, Dong XW, Feldman JL (2000) Synaptic control of motoneuronal excitability. Physiol Rev 80: 767-852.
9. Sandyk R (2006) Serotonergic mechanisms in amyotrophic lateral sclerosis. Int J Neurosci 116: 775-826.
10. Bertel O, Malessa S, Sluga E, Hornykiewicz O (1991) Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord. Brain Res 566: 54-60.
11. Forrest V, Ince P, Leitch M, Marshall EF, Shaw PJ (1996) Serotonergic neurotransmission in the spinal cord and motor cortex of patients with motor neuron disease and controls: quantitative autoradiography for 5-HT1a and 5- HT2 receptors. J Neurol Sci 139 Suppl: 83-90.
12. Sofic E, Riederer P, Gsell W, Gavranovic M, Schmidtke A, et al. (1991) Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm Park Dis Dement Sect 3: 133-142.
13. Turner MR, Rabiner EA, Hammers A, Al-Chalabi A, Grasby PM, et al. (2005) [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain 128: 896-905.
14. Lesch KP, Wolozin BL, Murphy DL, Reiderer P (1993) Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 60: 2319-2322.
15. Sneddon JM (1973) Blood platelets as a model for monoamine-containing neurones. Prog Neurobiol 1: 151-198.
16. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, et al. (1993) Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A 90: 2542-2546.
17. Alvarez JC, Cremniter D, Lesieur P, Gregoire A, Gilton A, et al. (1999) Low blood cholesterol and low platelet serotonin levels in violent suicide attempters. Biol Psychiatry 45: 1066-1069.
18. Alvarez JC, Gluck N, Arnulf I, Quintin P, Leboyer M, et al. (1999) Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther 66: 617-624.
19. Muck-Seler D, Presecki P, Mimica N, Mustapic M, Pivac N, et al. (2009) Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 33: 1226-1231.
20. Huey ED, Putnam KT, Grafman J (2006) A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 66: 17-22.
21. Strong MJ (2008) The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 9: 323-338.
22. Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40: 288-295.
23. Csernansky JG, Sheline YI (1993) Abnormalities of serotonin metabolism and nonpsychotic psychiatric disorders. Ann Clin Psychiatry 5: 275-281.
24. Spreux-Varoquaux O, Alvarez JC, Berlin I, Batista G, Despierre PG, et al. (2001) Differential abnormalities in plasma 5-HIAA and platelet serotonin concentrations in violent suicide attempters: relationships with impulsivity and depression. Life Sci 69: 647-657.
25. Hillemacher T, Grassel E, Tigges S, Bleich S, Neundorfer B, et al. (2004) Depression and bulbar involvement in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 5: 245-249.
26. McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA (1994) Survival in amyotrophic lateral sclerosis. The role of psychological factors. Arch Neurol 51: 17-23.
27. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, et al. (2005) Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord 6: 37-44.
28. Guicheney P (1988) Human platelet serotonin content: methodological aspects and physiological variations. Methods Find Exp Clin Pharmacol 10: 253-258.
29. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, et al. (2009) Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler 10: 310-323.
30. Flachaire E, Beney C, Berthier A, Salandre J, Quincy C, et al. (1990) Determination of reference values for serotonin concentration in platelets of healthy newborns, children, adults, and elderly subjects by HPLC with electrochemical detection. Clin Chem 36: 2117-2120.
31. Turner BJ, Lopes EC, Cheema SS (2003) The serotonin precursor 5-hydroxytryptophan delays neuromuscular disease in murine familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 4: 171-176.
32. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM (2003) The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 96: 635-642.
33. Tecott LH (2007) Serotonin and the orchestration of energy balance. Cell Metab 6: 352-361.
34. Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loeffler JP (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A 101: 11159-11164.
35. Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, et al. (2009) A serotonindependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138: 976-989.
36. Lacomblez L, Doppler V, Beucler I, Costes G, Salachas F, et al. (2002) APOE: a potential marker of disease progression in ALS. Neurology 58: 1112-1114.
37. Landers JE, Melki J, Meininger V, Glass JD, van den Berg LH, et al. (2009) Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 106: 9004-9009.
38. Sussmuth SD, Sperfeld AD, Hinz A, Brettschneider J, Endruhn S, et al. CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology 74: 982-987.
39. Alvarez JC, Gluck N, Fallet A, Gregoire A, Chevalier JF, et al. (1999) Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor for antidepressant response? Psychopharmacology (Berl) 143: 97-101.
40. Radat F, Berlin I, Spreux-Varoquaux O, Elatki S, Ferreri M, et al. (1996) Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study. Psychopharmacology (Berl) 127: 370-376.